Chong H. Yan

12 Middle Wulumuqi Road
Shanghai, 200040, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Real-world implications of efgartigimod in managing refractory myasthenia gravis.

Real-world implications of efgartigimod in managing refractory myasthenia gravis.

Journal: Expert opinion on biological therapy

Published: May 20, 2026

Patient preferences and willingness-to-pay for therapy in generalized myasthenia gravis: a large-scale discrete choice experiment in China.

Patient preferences and willingness-to-pay for therapy in generalized myasthenia gravis: a large-scale discrete choice experiment in China.

Journal: Frontiers in immunology

Published: January 26, 2026

Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.

Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.

Journal: Frontiers in immunology

Published: January 12, 2026

Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long-Term Real-World Study.

Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long-Term Real-World Study.

Journal: European journal of neurology

Published: December 02, 2025

Phospho-MLKL Upregulation in Immune-Mediated Necrotizing Myopathy: Implications for Disease Pathophysiology and Diagnosis.

Phospho-MLKL Upregulation in Immune-Mediated Necrotizing Myopathy: Implications for Disease Pathophysiology and Diagnosis.

Journal: Neuropathology : official journal of the Japanese Society of Neuropathology

Published: December 01, 2025

Good's syndrome and infections in a large retrospective cohort of thymoma.

Good's syndrome and infections in a large retrospective cohort of thymoma.

Journal: Frontiers in immunology

Published: October 27, 2025

Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis.

Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis.

Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Published: October 11, 2025

1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.

1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.

Journal: European journal of neurology

Published: October 06, 2025

Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.

Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.

Journal: Frontiers in immunology

Published: October 01, 2025

In-Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis.

In-Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis.

Journal: Annals of clinical and translational neurology

Published: September 16, 2025

Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study.

Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study.

Journal: Clinical immunology (Orlando, Fla.)

Published: July 05, 2025

The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.

The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.

Journal: Neurocritical care

Published: May 14, 2025

Showing 1-12 of 53

Last Updated: 09/26/2026